Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone
Discontinuation of medication due to adverse events · patients with non‐muscle invasive bladder cancer
Intravesically administered BCG alternating with IFN‐α showed no clear difference in discontinuation of therapy due to adverse events compared with intravesically administered BCG alone (low certainty).
1 finding from 1 review
- Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating… 2017 · Cochrane Headline outcomes onlyRR 2.97 [0.31, 28.09]1 study · 205 participantsLow